Published in Gene Therapy Weekly, August 17th, 2000
Such preparations are often referred to as "replication-competent-adenovirus-free" or "RCA-free" adenovectors, and provide significant advantages when used as tools for new product discovery and for therapeutic applications.
"The field of gene therapy has expended substantial efforts to create RCA-free adenovectors," said Dr. Paul H. Fischer, GenVec. "We are pleased that GenVec received this broad patent that recognizes our pioneering efforts in this area. This...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.